Sitagliptin for recurrent grade 4 glioma
Treatments studied
Part of Cancer clinical trials.
This trial tests whether the diabetes drug sitagliptin (Januvia) can help slow or shrink a recurrent grade 4 glioma (a type of brain tumor). It's for people whose tumor has come back after standard treatment and who have not used sitagliptin or Avastin before.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- Your grade 4 glioma has come back or progressed after initial treatment.
- You have not had sitagliptin or bevacizumab for this tumor before.
- You can swallow whole tablets and are in reasonably good health (ECOG 0-2).
- Your blood counts, kidney, and liver function are within safe limits.
- You do not have uncontrolled diabetes, heart problems, or a bleeding disorder.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether sitagliptin, a medicine usually used for diabetes, can help people with a fast-growing type of brain tumor (grade 4 glioma). You will take sitagliptin before your planned surgery, and researchers will study how it affects your tumor.
This trial tests a combination of two drugs—APG-157 (an oral plant-based medicine) and bevacizumab (Avastin)—for people with recurrent high-grade brain tumors that have already been treated with standard therapies. The goal is to see if adding APG-157 can help control the tumor better.
This trial studies sintilimab (an immune checkpoint medicine) plus low-dose bevacizumab (Avastin) in people with glioblastoma whose cancer has come back. It may help slow recurrence and improve outcomes by boosting the immune system while also limiting tumor blood supply.
This Phase 2 study tests tislelizumab (an anti–PD-1 immune therapy) combined with low-dose bevacizumab (Avastin) for recurrent glioblastoma that has already been treated with bevacizumab. If you qualify, you may be offered a new combination approach aimed at slowing tumor growth.
This trial tests a new injection called BC008-1A for people with a grade 4 glioma (a type of brain cancer) that has come back after standard treatment. The goal is to see if the drug can help control the tumor and improve outcomes.
This trial tests a combination of two experimental drugs, CTX-009 and CTX-471, for people whose glioblastoma has returned. The goal is to see if these drugs can help control the tumor.
Hear when a new Glioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.